Edition:
United States

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

3.14USD
23 Mar 2017
Change (% chg)

$-0.04 (-1.26%)
Prev Close
$3.18
Open
$3.18
Day's High
$3.22
Day's Low
$3.12
Volume
222,402
Avg. Vol
335,697
52-wk High
$3.65
52-wk Low
$1.41

AMRN.OQ

Chart for AMRN.OQ

About

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $865.16
Shares Outstanding(Mil.): 272.06
Dividend: --
Yield (%): --

Financials

  AMRN.OQ Industry Sector
P/E (TTM): -- 48.09 29.63
EPS (TTM): -0.41 -- --
ROI: -80.98 -2.54 13.01
ROE: -- 5.17 14.16

BRIEF-Amarin reaches the onset of about 80 pct of the target aggregate number within the reduce-it study

* Amarin reaches the onset of approximately 80% of the target aggregate number of primary major adverse cardiovascular events within the reduce-it study

Mar 16 2017

BRIEF-Amarin files for resale by the selling shareholders' of up to 10.4 mln shares- SEC filing

* Amarin Corp Plc files for resale by the selling shareholders of up to 10.4 million American Depositary Shares - SEC filing Source text for Eikon: Further company coverage:

Mar 01 2017

BRIEF-Amarin Corp files for potential mixed shelf - SEC filing

* Amarin Corporation Plc files for potential mixed shelf; size not disclosed - sec filing Source text for Eikon: Further company coverage:

Mar 01 2017

BRIEF-Amarin reports posts Q4 loss per share $0.10

* Amarin reports record fourth quarter and full year 2016 financial results and provides update on operations

Feb 28 2017

BRIEF-Amarin says debt restructuring and related private placement of exchangeable senior notes

* Amarin announces debt restructuring and related private placement of exchangeable senior notes

Jan 20 2017

BRIEF-Amarin Q3 adjusted non-gaap loss per share $0.08

* Maintaining guidance on 2016 net product revenue at $112-$125 million

Nov 03 2016

More From Around the Web

Earnings vs. Estimates